Chang Gung Memorial Hospital: Carcinoma trials

The registry lists 16 Carcinoma studies with Chang Gung Memorial Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 1Phase 2 4Phase 3 1Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 Cm and Microvascular InvasionRecruitingNCT06628661
• Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaRecruitingNCT06327269Early Phase 1
• Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular CarcinomaRecruitingNCT06034977Phase 2
• Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal CarcinomaCompletedNCT06676293Not applicable
• Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer IndexStatus unknownNCT05063019Not applicable
• Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal CarcinomaCompletedNCT04417985Not applicable
• The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular CarcinomaCompletedNCT04296058
• Hypermethylation of VTRNA2-1 Promoter in HCC OutcomeCompletedNCT04177316
• Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT GenotypeTerminatedNCT03608878Phase 2
• PET and MRI in Prognosis Prediction of NPCCompletedNCT03429868Not applicable
• Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+Status unknownNCT03121313Phase 2
• Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02761291Phase 1
• Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular CarcinomaStatus unknownNCT02640924Phase 3
• Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular CarcinomaStatus unknownNCT02504983Phase 4
• Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma RecurrenceCompletedNCT02447679Phase 2
• Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor RiskTerminatedNCT00937612Not applicable